MRI / Ultrasound Fusion With Contrast-Enhanced Ultrasound Guidance
Prostatic Neoplasms
About this trial
This is an interventional diagnostic trial for Prostatic Neoplasms focused on measuring Prostatic Neoplasms, Magnetic Resonance Imaging, MRI / Ultrasound Fusion, Contrast-Enhanced Ultrasound (CEUS)
Eligibility Criteria
Inclusion Criteria:
- Adults ( aged 21 years or greater), English speaking patients
Exclusion Criteria:
- Patients who are unable to provide informed consent
- Patients who have had previous reaction to any contrast agent at any point in the past
- Patients who have had previous septic infection from prostate biopsies at any point in the past
- Patients who have a right-to-left, bi-directional, or transient right-to-left cardiac shunts.
- Patients undergoing extracorporeal shock wave lithotripsy for urinary calculi.
- Patients with pre-existing cardiopulmonary compromise including, but not limited to, acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, serious ventricular arrhythmias or respiratory failure, including patients receiving mechanical ventilation
Sites / Locations
- Vancouver Coastal Health (VCHRI/VCHA)
Arms of the Study
Arm 1
Active Comparator
Definity Perflutren Suspension
Injection of Definity Perflutren Injectable Suspension- which travels in the bloodstream throughout the body. These microbubbles are identifiable on ultrasound imaging, and studies of the liver and kidney have identified it as a useful adjunct to identifying vascular lesions. Areas of regular blood flow will not have as large a concentration of the microbubble agent as will areas that have increased blood flow and neovascularisation. It has been well documented that cancerous solid lesions undergo neovascularisation and have increased blood flow to the area.